Search

Your search keyword '"Svegliati Baroni, Gianluca"' showing total 509 results

Search Constraints

Start Over You searched for: Author "Svegliati Baroni, Gianluca" Remove constraint Author: "Svegliati Baroni, Gianluca"
509 results on '"Svegliati Baroni, Gianluca"'

Search Results

3. Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma

4. Hypoalbuminemia and Risk of Portal Vein Thrombosis in Cirrhosis

5. Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study

6. Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care

8. Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease

9. A global research priority agenda to advance public health responses to fatty liver disease

10. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs

11. Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors

12. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma

13. Surveillance for hepatocellular carcinoma with a 3-months interval in “extremely high-risk” patients does not further improve survival

15. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)

16. THU-161 Hepatic sarcoidosis diagnosis and management: an italian multicenter study

17. THU-472-YI Sorafenib as a second-line treatment after failure of Atezolizumab/Bevacizumab

18. WED-293 Effectiveness of on different models of care based on Fibrosis-4 and/or liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease

19. SAT-477-YI The impact of etiologyon patterns of progression of advanced HCC

20. Global prevalence of MAFLD-related hepatocellular carcinoma: A systematic review and meta-analysis

21. Research Strands in Dermatology and Gastroenterology Units of Department of Clinical and Molecular Sciences in Polytechnic Marche University

22. Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment

23. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

25. Characteristics and outcome of anti-hepatitis D virus positive patients with hepatocellular carcinoma.

26. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial

28. List of contributors

30. Further decompensation in cirrhosis: Results of a large multicenter cohort study supporting Baveno VII statements

31. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

32. Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group

36. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs

37. The Italian data on SARS-CoV-2 infection in transplanted patients support an organ specific immune response in liver recipients

39. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma

41. Prophylaxis of HBV-recurrence after liver transplantation in patients with HCC: risk of HCC recurrence from a large, multicentre retrospective study from Italy

42. Primary sclerosing cholangitis recurrence after liver transplantation: a nationwide survey in Italy

43. Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced non-alcoholic fatty liver disease

44. Further decompensation as a new prognostic stage in cirrhosis. Results of a large multicenter cohort study supporting Baveno VII statements

45. Burden of non-alcoholic fatty liver disease and usefulness of non-invasive tests to identify advanced liver disease in patients with type 2 diabetes mellitus: interim analysis of an Italian prospective multicentre study

47. Corrigendum to ‘Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)’ Nutrition, Metabolism and Cardiovascular diseases volume 32 issue 1 (2022) 1-16

48. Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease

49. Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma

Catalog

Books, media, physical & digital resources